Bavarian Nordic A/S (CPH:BAVA)

Market Cap	14.81B +24.3%
Revenue (ttm)	5.96B -4.4%
Net Income	1.17B -11.2%
EPS	14.84 -10.7%
Shares Out	76.49M
PE Ratio	13.05
Forward PE	18.38
Dividend	n/a
Ex-Dividend Date	n/a

Volume	69,121
Average Volume	229,255
Open	193.50
Previous Close	193.60
Day's Range	193.00 - 197.80
52-Week Range	164.05 - 244.80
Beta	0.95
RSI	54.68
Earnings Date	May 13, 2026

About Bavarian Nordic

Bavarian Nordic A/S develops, manufactures, and supplies life-saving vaccines. The company offers non-replicating smallpox and monkeypox vaccines under the IMVAMUNE, IMVANEX, and JYNNEOS names; rabies vaccine for human use under the Rabipur/RabAvert name; tick-borne encephalitis vaccine under the Encepur name; Vaxchora, an oral vaccine for immunization against cholera; and Vivotif/Typhoral, an oral vaccine for immunization against typhoid fever. It is also developing MVA-BN WEV, that is in phase 2 trial for the treatment of encephalitis viruses...

• Industry: Biotechnology
• Sector: Healthcare
• Founded: 1992
• Employees: 1,861
• Stock Exchange: Copenhagen Stock Exchange
• Ticker Symbol: BAVA

Financial Performance

In 2025, Bavarian Nordic's revenue was 6.24 billion, an increase of 9.23% compared to the previous year's 5.72 billion. Earnings were 1.38 billion, an increase of 39.21%.